Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Workman

Showing results (71-80 of 315) with videos related to

Pageof 32
Sort By:
Oncotarget|January 29, 2016
Blocking the survival of the nastiest by HSP90 inhibitionPaul Workman, Paul A Clarke, Bissan Al-Lazikani
Future Medicinal Chemistry|November 29, 2019
Public resources for chemical probes: the journey so far and the road aheadAlbert A Antolin, Paul Workman, Bissan Al-Lazikani
Expert Opinion on Drug Discovery|July 10, 2019
Transforming cancer drug discovery with Big Data and AIPaul Workman, Albert A Antolin, Bissan Al-Lazikani
Expert Opinion on Emerging Drugs|May 25, 2004
Histone modification enzymes: novel targets for cancer drugsRebecca Kristeleit, Lindsay Stimson, Paul Workman, et al.
Annals of the New York Academy of Sciences|May 22, 2007
Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stressPaul Workman, Francis Burrows, Len Neckers, et al.
Cancer Cell|August 17, 2013
HSF1 in TranslationEmmanuel de Billy, Paul A Clarke, Paul Workman
Drug Discovery Today|December 26, 2021
Enhancing access to innovative cancer drugs: Cross-sector consensus on a way forward to benefit patientsRichard Hoey, Eva Sharpe, Angela Kukula, et al.
Cell Cycle (Georgetown, Tex.)|February 7, 2009
Death by chaperone: HSP90, HSP70 or both?Marissa V Powers, Paul A Clarke, Paul Workman
Cancer Cell|September 6, 2008
Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosisMarissa V Powers, Paul A Clarke, Paul Workman
Molecular Cancer Therapeutics|February 20, 2007
The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discoveryNicola F Smith, Florence I Raynaud, Paul Workman
Pageof 32

Showing results (71-80 of 315) with videos related to

Sort By:
Pageof 32
Oncotarget|January 29, 2016
Blocking the survival of the nastiest by HSP90 inhibitionPaul Workman, Paul A Clarke, Bissan Al-Lazikani
Future Medicinal Chemistry|November 29, 2019
Public resources for chemical probes: the journey so far and the road aheadAlbert A Antolin, Paul Workman, Bissan Al-Lazikani
Expert Opinion on Drug Discovery|July 10, 2019
Transforming cancer drug discovery with Big Data and AIPaul Workman, Albert A Antolin, Bissan Al-Lazikani
Expert Opinion on Emerging Drugs|May 25, 2004
Histone modification enzymes: novel targets for cancer drugsRebecca Kristeleit, Lindsay Stimson, Paul Workman, et al.
Annals of the New York Academy of Sciences|May 22, 2007
Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stressPaul Workman, Francis Burrows, Len Neckers, et al.
Cancer Cell|August 17, 2013
HSF1 in TranslationEmmanuel de Billy, Paul A Clarke, Paul Workman
Drug Discovery Today|December 26, 2021
Enhancing access to innovative cancer drugs: Cross-sector consensus on a way forward to benefit patientsRichard Hoey, Eva Sharpe, Angela Kukula, et al.
Cell Cycle (Georgetown, Tex.)|February 7, 2009
Death by chaperone: HSP90, HSP70 or both?Marissa V Powers, Paul A Clarke, Paul Workman
Cancer Cell|September 6, 2008
Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosisMarissa V Powers, Paul A Clarke, Paul Workman
Molecular Cancer Therapeutics|February 20, 2007
The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discoveryNicola F Smith, Florence I Raynaud, Paul Workman
Pageof 32